IASO

Beyond's analysis on IASO

• 2026-09-16 — IASO Bio secures FDA clearance for first China-origin lentiviral in vivo CAR-T therapy

Recent news mentioning IASO

• 2026-09-16 — IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
• 2026-08-13 — IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
• 2026-08-12 — Diasorin declassata a "sell", per Ubs salgono pressioni competitive

Appears alongside

• FDA
• IND
• MediSix

Browse the full archive →